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Acute respiratory virus infections predispose the cystic fibrosis (CF) lung to chronic bacterial colonization, which contributes to high 
mortality. For reasons unknown, respiratory virus infections have a prolonged duration in CF. Here, we demonstrate that mice car-
rying the most frequent cystic fibrosis transmembrane conductance regulator (CFTR) mutation in humans, ΔF508, show increased 
morbidity and mortality following infection with a common human enterovirus. ΔF508 mice demonstrated impaired viral clearance, 
a slower type I interferon response and delayed production of virus-neutralizing antibodies. While the ΔF508 mice had a normal 
immune cell repertoire, unchanged serum immunoglobulin concentrations and an intact immune response to a T-cell–indepen-
dent antigen, their response to a T-cell–dependent antigen was significantly delayed. Our studies reveal a novel function for CFTR 
in antiviral immunity and demonstrate that the ΔF508 mutation in cftr is coupled to an impaired adaptive immune response. This 
important insight could open up new approaches for patient care and treatment.
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Cystic fibrosis (CF) is caused by mutations in a chloride channel 
encoded by the cystic fibrosis transmembrane conductance reg-
ulator (CFTR) gene. It is one of the most common monogenic 
diseases in the Caucasian population. CFTR is expressed on the 
apical membrane of most epithelial cells and defective CFTR 
leads to disturbances in the electrolyte balance in secretory epi-
thelia. This negatively affects the function of epithelial organs, 
including the lungs, intestine, and pancreas [1].
Although improved treatments have increased survival 
rates from a few years to over 40 years for most CF patients, 
recurrent and chronic bacterial lung infections resulting in res-
piratory failure remain a major cause of early mortality. At pre-
sent it is not understood why individuals with CF suffer from 
such life-threatening infections. Current observations suggest 
that viral infections (eg, enteroviruses including rhinovirus, 
respiratory syncytial virus [RSV], etc.), may be important con-
tributing factors, as they predispose the lower airways to bacte-
rial colonization [2, 3].
For reasons unknown, individuals with CF suffer from virus 
infections with a prolonged duration [4, 5]. Considering the 
aforementioned clinical importance of virus infections in CF 
[2, 3], knowledge regarding how mutations in CFTR affect the 
antiviral immune response is warranted. An impaired innate 
antimicrobial defense in epithelial cells, as demonstrated in cells 
from the lung [6], may contribute to excessive virus replication. 
Several studies have shown that CFTR is expressed by immune 
cells, including mononuclear monocytes and lymphocytes 
[7–11], but little is known about the functional role of CFTR 
in immune cells [9, 12] and how mutations in CFTR affect the 
immune responses to infections.
Enteroviruses such as rhinoviruses and Coxsackie B viruses 
(CVBs) are a common cause of respiratory tract infections (eg, 
“the common cold”) both in healthy individuals and patients 
with CF [2, 5, 13]. Rhinoviruses infect and replicate in the upper 
airways whereas CVBs infect via both the fecal–oral route and 
the respiratory tract, and have a broader tissue tropism [14]. 
Studies examining the immune response to rhinoviruses were 
long hampered by a lack of suitable small animal models, while 
CVB-infected mice develop diseases similar to those seen in 
humans [15] and have been used extensively to study the host 
immune responses to infection (eg, [15–17]).
The role for CFTR in the host immune response to CVB in-
fection has not been investigated. In contrast, interferons (IFNs) 
and several IFN-inducible genes (ISGs) have been implicated 
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in the host response to such infections. Studies in animal mod-
els have shown that type I  (IFN-α and IFN-β), but not type II 
(IFN-γ) interferons, are essential for the early immune response 
to, and survival following, CVB infections [18]. A more recently 
described group of IFNs, type III IFNs (IFN-λs), have so far not 
been studied under in vivo conditions, but have an antiviral effect 
against CVBs in vitro [19, 20]. ISGs shown to be important in the 
defense against CVBs include genes coding for proteins involved 
in the recognition of viruses (eg, TLR3 and MDA5) and in anti-
viral defense (eg, iNOS, PKR, OAS) (eg, [16, 17, 21, 22]). Type 
I IFNs are also known to be of general importance for the acti-
vation of the adaptive antiviral immune response [23–25]. The 
production of neutralizing antibodies after infection that prevent 
the virus from spreading and that also assist in clearing infectious 
viral particles from the body, is particularly important during en-
terovirus infections both in mouse and humans [26–28].
The goal of this study was to increase our knowledge and 
understanding of the defective antiviral immune response 
linked with mutations in CFTR. We hypothesized that delayed 
virus clearance in hosts with a mutated CFTR is due to a defect 
in extrapulmonary antiviral immunity. To address this hypoth-
esis, we made use of the Cftrtm1EUR mouse model (here denoted 
ΔF508) carrying the cftr mutation most commonly found in 
humans, F508del [29, 30]. The normal survival rates of the 
ΔF508 mouse model and the broad tropism of the enterovirus 
Coxsackievirus B3 (CVB3) enabled us to study both the sys-
temic and the tissue-specific immune responses to enterovirus 
infection in a host with a defective CFTR. We demonstrate that 
the ΔF508 mutation causes delayed virus clearance, which cul-
minates in a high mortality rate. Importantly, we link delayed 
virus clearance to a defective adaptive immune response and we 
demonstrate the therapeutic potential of passive immunization.
METHODS
The present study made use of the Cftrtm1EUR mouse model 
(homozygous ΔF508 mice and wild-type (wt) littermate con-
trols) on a C57BL/6J background [29, 30] and coxsackievirus 
B3 Nancy (CVB3). A detailed material and methods description 
is given in the Supplementary Material Methods.
Ethics Statement
The mice were housed and experiments performed according to 
local and national regulations, and the study was approved by 
the Stockholm South Animal Ethics Board.
RESULTS
Decreased Survival and Increased Viral Loads in Organs of ΔF508 Mice 
Challenged With CVB3
To evaluate if the common ΔF508 mutation in the cftr gene 
affects susceptibility to enterovirus infection, we infected ΔF508 
mice and wild-type (wt) littermate controls with two different 
doses of CVB3 via the intraperitoneal route. While both wt and 
ΔF508 mice eventually succumbed to infection with the higher 
virus dose (Figure 1A), the median survival time was longer in wt 
animals (10 days) compared to ΔF508 mice (4 days). Even with a 
virus dose that was not lethal to the wt mice, the majority of ΔF508 
mice died after infection (Figure 1B). These results showed that 
ΔF508 mice have an impaired ability to survive a CVB3 infection.
Viremia measurements revealed no differences between the 
infected wt and ΔF508 mice (Figure 2A), suggesting that the ΔF508 
mutation did not affect early viral replication and dissemination. 
CVB3, however, has a broad tissue tropism and virus titers in 
organs from systemically infected animals normally peak between 
days 3 and 5 postinfection [15, 21]. By measuring infectious virus 
particles in organs collected on day 5 postinfection we detected 
significant differences in the titers of replicating virus between the 
wt and ΔF508 mice (Figure 2B). At the same time point, substan-
tial histopathological signs of infection in certain organs from the 
infected mice, including extensive damage to the exocrine pan-
creas, mild hepatitis, and some disruption of the splenic structure 
were observed. No major differences were observed, however, 
between the wt and ΔF508 mice (Supplementary Figure 1).
By day 7 postinfection there were even more striking differ-
ences between wt and ΔF508 mice in terms of virus replication 
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Figure 1. ΔF508 mice demonstrate an increased mortality rate after infection with Coxsackievirus. ΔF508 mice (dotted lines) and wild-type (wt) littermate controls (solid 
lines) were infected with Coxsackievirus B3 (CVB3) and monitored for 28 days. A, Wt (n = 10) and ΔF508 (n = 9) mice infected with 104 plaque-forming units (PFU) CVB3/mouse. 
B, wt (n = 3) and ΔF508 (n = 10) infected with 102 PFU CVB3/mouse. Log-rank (Mantel–Cox) test.
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(Figure 2C). Thus, CVB3 continued to replicate at a high rate 
in ΔF508 at a time point when virus titers declined in wt mice.
A Delayed Induction of IFN-α Production by ΔF508 Mice in Response to 
Poly(I:C)
The importance of type I  IFNs for survival after CVB infec-
tion [18] led us to assess IFN-α levels in the CVB3-infected 
mice. Based on previous studies [21], serum IFN-α levels were 
measured at 48 hours post CVB3 infection and we discovered a 
trend towards a lower production of IFN-α in ΔF508 mice com-
pared to wt mice (Figure 3A). To make sure each animal was 
exposed to the same amount of viral stimuli, we employed an 
alternative method to determine the IFN-α response to infec-
tion. Polyinosinic:polycytidylic acid (poly(I:C)) is a commonly 
used mimic of viral replication intermediates that induces IFN 
production. It is recognized by the same pattern recognition 
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Figure 2. Sustained high level viral replication in ΔF508 mice after infection with Coxsackievirus. Wild-type (wt; black bars) and littermate ΔF508 mice (white bars) were 
infected with Coxsackievirus B3 (102 plaque-forming units [PFU]/mouse). A, Blood was harvested on days 3 (n = 3–5 animals per genotype), 4 (n = 9–12 animals per genotype), 
and 5 (n = 3–4 animals per genotype) postinfection for viremia measurements using plaque assay. B, Titers of replicating virus particles in organs harvested on day 5 postin-
fection were measured by plaque assay (n = 4–7 animals per genotype). C, Titers of replicating virus particles in organs harvested on day 7 postinfection were measured by 
plaque assay (n = 6–8 animals per genotype). A–C, Plaque assay results are presented as log10(PFU/g wet tissue or mL blood) and represent means ± standard deviation *P 
< .05, **P < .01, ***P < .001 and n.s, nonsignificant, Mann–Whitney test.
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Figure 3. ΔF508 mice show a delayed interferon-alpha (IFN-α) response after stimulation with poly(I:C). A, Wild-type (wt; n = 6) and ΔF508 (n = 8) mice were infected with 
Coxsackievirus B3 (104 plaque-forming units [PFU]/mouse) and serum was drawn on day 2 postinfection. B, Wt (n = 8–14 per time point) and ΔF508 (n = 6–8 per time point) 
mice were stimulated with poly(I:C) (100 μg/mouse, intraperitoneal) and serum was drawn at 2 hours and 4 hours after stimulation. IFN-α levels in serum from wt mice (black 
bars) and ΔF508 mice (white bars) from infected mice (A) or mice stimulated with Poly(I:C) (B) were measured using enzyme-linked immunosorbent assay. Data is presented 
as means ± SD *P < .05, **P < .01, and ***P < .001, two-way analysis of variance with Holm–Sidak’s correction.
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receptors (PRRs) as enteroviruses (TLR3 and MDA5 [15, 21]) 
and is known to elicit an IFN response rapidly after administra-
tion to mice [31, 32].
Before stimulating the animals with poly(I:C) we mea-
sured the basal mRNA expression levels of the PRRs TLR3 
and MDA5 in different organs of uninfected wt and ΔF508 
mice. No differences in their expression levels were observed 
(Supplementary Figure  2). We then injected mice with 
poly(I:C) and measured serum IFN-α levels. At 2 hours post-
injection, ΔF508 mice produced significantly lower levels of 
IFN-α compared to wt mice. In contrast, at 4 hours postinjec-
tion this difference was no longer observed, suggesting that 
the F508del mutation caused a delay in the IFN-α response 
upon poly(I:C) stimulation (Figure 3B).
IFN-α is primarily produced by immune cells (mainly den-
dritic cells [DC]), while IFN-β and type III IFNs are produced 
by both immune and parenchymal cells (reviewed in [33]). 
Hence, we also measured IFN-β and IFN-λ mRNA expres-
sion levels in different organs from poly(I:C)-stimulated wt 
and ΔF508 mice. Both groups responded to the injection 
but there were no statistically significant differences in the 
IFN-β (Supplementary Figure 3) and IFN-λ (Supplementary 
Figure  4) mRNA expression levels between the wt and 
ΔF508 mice.
Together, these studies revealed that ΔF508 mice have a 
delayed IFN-α response to viral stimuli.
ΔF508 Mice Have no Major Impairment in the Expression of Antiviral 
Defense Genes
The basal expression levels of iNOS and OAS mRNA did not 
differ between the wt and ΔF508 mice (Supplementary Figures 
5A and B), whereas the expression of both iNOS and OAS was 
increased in most organs in both wt and ΔF508 mice follow-
ing poly(I:C) stimulation and only a few minor differences were 
observed between the wt and ΔF508 mice (Supplementary 
Figure 5A and B). These are unlikely to contribute dramatically 
to the lower survival of ΔF508 mice following virus challenge.
Impaired Production of Virus-neutralizing Antibodies in ΔF508 Mice
We next investigated if the delay in the innate response to virus 
was mimicked in an impaired adaptive immune response. Using 
enzyme-linked immunosorbent assay (ELISA) we measured 
serum levels of IgM and IgG virus-binding antibodies. At day 
5 postinfection around half of the wt mice had detectible IgM 
and IgG levels, while the levels in ΔF508 mice remained close 
to the detection limit (Figure 4A). Two days later (day 7 post-
infection), all mice had a detectible IgM and IgG responses to 
the virus. However, the antibody titers in serum from the ΔF508 
mice were significantly lower than in wt mice (Figure 4A).
As not all of the antibodies that bind to a virus are capable of 
preventing infection, we next assessed whether the antibodies 
produced by the infected mice were able to neutralize CVB rep-
lication. In wt mice, serum neutralizing antibodies had already 
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Figure 4. Mice carrying the ΔF508 mutation have a delayed antibody response to Coxsackievirus B3 (CVB3). A, Wt and ΔF508 mice were infected with 102 PFU CVB3/
mouse. Virus-specific IgM and IgG antibodies were measured in serum samples harvested from infected animals on day 5 (n = 8–12 per genotype) and 7 (n = 3–5 per 
genotype) postinfection using a CVB3 virus like particles-specific enzyme-linked immunosorbent assay. B, C, Serum drawn on days 4 (n = 4–6 animals per genotype), 5 (n = 
7–15 animals per genotype), and 7 (n = 3–8 animals per genotype) postinfection were evaluated for the presence of neutralizing antibodies, as described in Supplementary 
Material Methods. B, The percentage of antibody-positive wt (black bars) and ΔF508 (white bars) mice at the indicated days postinfection is shown. C, The percentage of 
antibody-positive wt mice (black bars, n = 8) and ΔF508 mice (white bars, n = 3) at indicated serum dilutions on day 7 postinfection. Data in A is presented as mean ± SD *P 
< .05, **P < .01. Mann–Whitney test (A) and Fisher exact test (B, C). Abbreviation: OD, optical density.
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appeared by day 4 postinfection (Figure 4B). In stark contrast, 
none of the ΔF508 mice had detectible levels of neutralizing 
antibodies at this time point. On day 5 postinfection over 60% of 
the wt mice capable to neutralize virus, while no such neutraliza-
tion was observed in serum harvested from ΔF508 mice. On day 
7 postinfection both wt and ΔF508 mice were antibody positive 
(Figure 4B). However, the titers of neutralizing antibodies were 
significantly lower in ΔF508 mice than in wt mice (Figure 4C). 
Taken together, this demonstrated that ΔF508 mice are impaired 
in their ability to efficiently raise antibodies against CVB3.
Passive Immunization Protects ΔF508 Mice From Infection
If the lack of a rapid and efficient antibody response to CVB3 
was the underlying cause of the increased viral replication and 
mortality seen in ΔF508 mice challenged with CVB3, it would 
be expected that the transfer of antibodies from previously 
infected mice should provide protection against infection. To 
both test this hypothesis, and to make a preclinical assessment 
of the therapeutic potential of the passive transfer of antibod-
ies for the protection of ΔF508 mice against viral infection, 
ΔF508 mice received either antibody positive or naive serum 
1 day before challenge with CVB3 and were followed until day 
7 postinfection The successful transfer of neutralizing antibod-
ies to the ΔF508 mice receiving immune serum was confirmed 
by neutralization assay (Figure  5A). Mice that received anti-
body-positive serum had significantly lower levels of viremia 
on days 3 and 4 postinfection (Figure 5B). These animals also 
had lower levels of replicating virus particles in different organs 
(Figure 5C), as well as less exocrine pancreatic tissue damage 
(Figure  5D). These results demonstrated that the transfer of 
neutralizing antibodies prevents CVB3 infection in ΔF508 mice.
ΔF508 Mice Display no Differences in Major Lymphocyte Populations and 
Have Normal Levels of IgM and IgG Antibodies at Steady State
The impaired antibody response to CVB3 infection suggested 
a deficiency in the immune system of ΔF508 mice. To test this 
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Figure 5. Passive immunization protects ΔF508 mice from Coxsackievirus B3 (CVB3) infection and tissue damage. Antibody-positive (immune) and negative (nonimmune) 
sera was prepared from previously infected wt mice, as described in the Supplementary Material Methods section. Passive immunizations were performed 24 hours prior to 
CVB3 challenge by the administration of 400 µl (intraperitoneal) immune or nonimmune sera to the ΔF508 mice. A, The neutralizing capacity of sera drawn at 24 hours after 
passive immunization was measured at 2 separate dilutions, 1:100 and 1:1000, as described in the Supplementary Material Methods. The percentage of animals that had 
sera with virus-neutralizing capacity is shown as the percentage of all animals in each respective group. Black and white bars indicate animals receiving immune (AB+; n = 
5) and nonimmune (AB−; n = 5) sera, respectively. B, C, Passively immunized ΔF508 mice were infected with CVB3 (102 plaque-forming units [PFU]/mouse). Blood was drawn 
on days 3 and 4 postinfection for viremia measurements (B). C, On day 7 postinfection, the mice were sacrificed and the indicated organs were retrieved for histological 
analysis and measurements of replicating virus particles. Note that in the group receiving nonimmune serum, one mouse had to be sacrificed on day 6 postinfection due to 
CVB3-induced illness. The results are presented as log10(PFU/g wet tissue or mL blood) and represents means ± SD. D, Representative images of pancreas sections from 
CVB3-infected ΔF508 mice receiving antibody-negative (AB−; n = 5) or antibody-positive (AB+; n  = 5) sera, respectively. Upper panels, H&E staining. Lower panels, immuno-
histochemistry using primary antibody detecting insulin positive cells within the pancreas parenchyma. Original magnification × 10. *P < .05, **P < .01. Fisher exact test (A) 
and Mann–Whitney test (B, C).
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hypothesis, we analyzed major lymphocyte populations (B and 
T cells, invariant natural killer T cells, and natural killer cells) 
in spleens from ΔF508 and wt littermate controls. We did not 
detect any statistically significant differences in the propor-
tions of any of the immune cell subsets studied (Supplementary 
Figure 6A–I).
Using ELISA, we measured total serum concentrations 
of IgM and IgG in naive ΔF508 and littermate control mice 
(Supplementary Figure  6J). This analysis failed to reveal any 
differences between ΔF508 and wt mice. Collectively, these 
analyses suggested that the ΔF508 polymorphism confers no 
generalized alterations in splenic lymphocyte development or 
changes in systemic immunoglobulin concentrations.
ΔF508 Mice Display a Delayed Response to a T-Cell–Dependent Antigen
We next performed a more detailed study examining the 
antibody responses in the ΔF508 mice. B cells can raise 
antibodies to antigens either in a T-cell–independent (TI) 
or T-cell–dependent (TD) manner [34]. By injecting mice 
with 2,4,6-trinitrophenyl (TNP)-Ficoll and measuring nitro-
phenyl (NP)-specific antibodies in serum, we investigated 
whether ΔF508 mice have a defective TI antibody response 
[35]. This analysis revealed no differences in the production 
of NP-specific IgM or IgG antibodies between ΔF508 and wt 
mice at any of the time points examined (Figure 6A). This is 
a strong indication that the ΔF508 mice have intact antibody 
responses to TI antigen.
To address whether the ΔF508 mice have a normal anti-
body response to a TD antigen, we made use of recombi-
nant Semliki Forest virus expressing beta-galactosidase 
(SFV-βGal) [36], which has previously been shown to elicit 
a strong antibody response in immunized mice [37]. Mice 
were injected with rSFV-βGal and the levels of βGal-specific 
antibodies were measured in serum samples drawn on days 
0, 5, 7, and 12 postinjection. ΔF508 mice had significantly 
lower levels of βGal-specific IgM and IgG antibodies on day 
7 postimmunization (Figure  6B). However, by day 12, this 
difference was no longer observed and the antibody levels in 
F508 mice were similar to those in wt mice (Figure 6B). This 
showed that the ΔF508 mice have the same ability to raise 
antibodies as wt mice, but that the time between antigen ex-
posure and fully activated antibody production is longer in 
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Figure 6. ΔF508 mice have an intact T-cell–independent antibody response but show a delayed response to a T-cell–dependent antigen. A, Wild-type (wt; n = 10; black 
circles) and ΔF508 (n = 7; open squares) mice were injected with the T-cell–independent antigen 2,4,6-trinitrophenyl (TNP)-Ficoll (10 µg/mouse, intraperitoneal [IP]). B, Wt (n 
= 6; black circles) and ΔF508 (n = 5; open squares) mice were challenged with the T-cell–dependent antigen recombinant Semliki Forest virus expressing beta-galactosidase 
(rSFV-βGal; 1 × 105 Infectious units [IU]/mouse, intravenous [IV]). Serum was drawn at the indicated time points (days 0, 5, 7, and 12 postinjection) and levels of nitrophenyl 
(NP)-specific antibodies in serum (A) and βGal (B) specific IgM and IgG were measured using enzyme-linked immunosorbent assay. Open squares and black circles represents 
wt and ΔF508 mice, respectively. Data are presented as mean ± standard deviation *P < .05, **P < .01. Mann−Whitney test. Abbreviation: OD, optical density.
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the ΔF508 mice, in a similar manner to that seen with CVB3 
infection.
DISCUSSION
Much research in CF has focused on the immune functions of 
the airways. However, several observations [38–40] indicate 
that the impact of a defective CFTR must be seen in a broader 
context, taking both the immune system and other organs into 
consideration. The present study used a well-characterized 
model for human infections with enteroviruses and demon-
strates that mice homozygous for ΔF508, the most common 
CFTR mutation in man, show increased mortality following a 
Coxsackievirus infection. A lower survival was accompanied by 
a reduced ability to attenuate virus replication in several organs, 
a delayed IFN-α response to viral stimuli, as well as the failure to 
efficiently raise neutralizing antibodies in response to infection.
A previous study showed that mice completely deficient in 
CFTR have a delayed clearance of RSV from the lungs, but did 
not provide a mechanistic explanation for this observation [41]. 
In the present study, experiments were conducted to identify 
the underlying cause of the greater mortality seen in ΔF508 
mice challenged with CVB3. As judged by viremia measure-
ments, no differences existed between the percentages of wt and 
ΔF508 mice that became infected with CVB3. This is in keep-
ing with most, but not all, studies, suggesting that human CF 
is not associated with more frequent viral infections (eg, [4, 5, 
42]). In contrast, significantly higher levels of infectious virus 
particles were measured in numerous organs from ΔF508 mice, 
suggesting that the ΔF508 mice are impaired in their ability to 
hinder viral replication and clear the virus. This novel observa-
tion deserved further investigation.
While we discovered a clear difference in the levels of IFN-α 
in the serum between wt and ΔF508 mice stimulated with 
poly(I:C), no or only small differences were observed in the 
mRNA expression of PRRs and ISGs. Thus, the decreased antivi-
ral immunity in ΔF508 mice appeared to result from alterations 
in immune cells rather than defects within nonlymphoid organs.
Variation in the levels of replicating virus particles in organs 
from wt and ΔF508 mice was apparent on day 5 postinfection, a 
time point after which the virus titers typically begin to decline 
in wt mice [16, 27]. Antibodies are particularly crucial in the 
clearance of enteroviruses in both mice and humans [26–28], 
and we noted that production of virus-binding antibodies and 
antibodies with virus-neutralizing capacity was delayed in the 
ΔF508 mice. These observations, coupled with the impaired 
clearance of replicating virus particles from organs and the pro-
tective effect seen with the transfer of antibody-positive sera, 
clearly suggested that a defective antibody response contributed 
to the uncontrolled virus replication and heightened mortality 
seen in ΔF508 mice. Indeed, it is very likely that the uncon-
trolled virus replication led to multiorgan failure and thereby 
the fatal outcome.
In analogy with human CF (eg, [43]), our analysis of rele-
vant immune cell subsets in wt and ΔF508 mice did not reveal 
any significant differences between the groups. Similarly, the 
levels of total IgM and IgG did not differ between the animals. 
Collectively, this suggest that the delayed antibody response 
in ΔF508 mice may be explained by a functional defect within 
the immune cell compartment or a loss or altered frequency of 
specific immune cell subtypes. The ΔF508 mice had a normal 
response to a TI antigen, suggesting that B-cell activation, anti-
body secretion, and isotype class switching are normal in these 
mice. Similar conclusions have been drawn in studies examin-
ing B cells in human CF (eg, [43]). Indeed, although individuals 
develop hypergammaglobulinemia in parallel with progression 
to more severe disease, most individuals with CF are hypogam-
maglobulinemic or have normal immunoglobulin levels early 
in life [43, 44].
Here, we discovered that the ΔF508 mice had a delayed 
response to a TD antigen. This observation shifts the focus to 
other cell types that are important in a TD antibody response, 
namely T cells and antigen presenting cells (eg, DC and mac-
rophages). Altered helper and cytotoxic T-cell functions have 
been reported in human CF [43, 45]. Defective DC functions 
have also been suggested to occur in human CF and the ΔF508 
mouse model, including altered cell numbers and altered anti-
gen presenting capacity [11, 30]. The observations of the DCs 
are interesting considering the difference seen in our studies in 
the production of IFN-α between wt and ΔF508 mice. Indeed, 
plasmacytoid DCs (pDCs) are the major producers of IFN-α 
in response to poly(I:C) [46] and some virus infections [47]. 
Although the present study did not examine the cellular source 
of the IFN-α, it provides an indication that pDC numbers may 
be lower or that DC function is impaired. IFNs are important 
for promoting a T-cell response and the maturation of B cells 
into antibody-secreting plasma cells [23–25]. Thus, it is tempt-
ing to speculate that the delayed IFN-α secretion may have con-
tributed to the slower production of neutralizing antibodies in 
the ΔF508 mice. Future studies should address whether there 
may be a defect in pDC or other DCs and T cells in the ΔF508 
mouse which might explain the delayed antibody response.
Infections with enteroviruses such as rhinoviruses are com-
mon in humans and show a prolonged duration in individuals 
with CF [4, 5], thereby contributing to CF lung exacerbations 
[5, 13, 48–50]. Here, we showed that passive immunization 
prevented aggressive infection and enterovirus-induced tissue 
damage in the ΔF508 mice. This indicates that intravenous 
immunoglobulin (IVIG) treatment could be useful in humans 
for quenching excessive virus particles while awaiting the acti-
vation of the adaptive immune response.
Another important implication of our findings is that indi-
viduals carrying the ΔF508 mutation may not only have altered 
antibody responses to viruses. Indeed, kinetics of the antibody 
responses to bacteria and vaccines may also be affected and 
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additional studies should be performed to assess the antibody 
response of the ΔF508 mice to these.
The life expectancy of patients with CF has increased dramat-
ically over the last decades, mainly as a result of improved treat-
ment and care. However, respiratory bacterial infections still 
remain a major risk factor for morbidity and mortality in CF. 
Respiratory viral infections increase the risk of chronic bacte-
rial colonization of the CF airways [48–50]. To our knowledge, 
our study is the first to demonstrate that a homozygote defect in 
cftr impairs the host immune response to a type of virus known 
to cause respiratory tract infections in CF patients [5, 13]. Our 
observations showing inefficient viral clearance in the ΔF508 
mice are in accord with the prolonged duration of respiratory 
virus infections observed in human CF [4, 5]. By providing a 
novel biological explanation of the delayed viral clearance, our 
study contributes to an increased understanding of both the 
role of CFTR in host antiviral defense and the impact of muta-
tions in cftr on immune functions, which could open up new 
approaches for patient care and treatment.
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